

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

MARK B. WILSON
PARTNER

INTERNET ADDRESS:
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: 512/536-3035



April 27, 2001

RECEIVED

MAY 04 2001

TECH CENTER 160002900

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

FILE: INDA:005USD1

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

4/27/2001
Date

Mark B. Wilson

Commissioner for Patents
Washington, DC 20231

RE: SN 09/626,616 "POLYNUCLEOTIDE ENCODING MU OPIOID RECEPTOR" - Lei Yu

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Amendment, an Information Disclosure Statement, Forms PTO-1449 and references (C39-C41).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is hereby authorized to deduct any necessary fees from Fulbright & Jaworski Deposit Account No. 50-1212/10020907/GNS.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Mark B. Wilson
Reg. No. 37,259104

MBW/mac

Encl.: As noted